Sunday, March 30, 2025 1:52:43 AM
Krisgo, I am looking forward to this coming week too.
My optimism. I believe the very segmented and compartmentalized cancer therapy market will be transformed into a single large green field opportunity because DCVax technology platform is a broad-spectrum cancer vaccine. I want to emphasize vaccine (efficacy, non-toxic, and immune memory) as opposed to drug (single antigen target, high risk for toxicity, and not-a-cure).
We Longs all need to stick together, remain disciplined, and trust our due diligence. The market manipulators are still trying to gaslight us into selling, trading, and or lend out our shares. The true potential though is to just hold. Short term has a major asymmetric upside opportunity, and long-term has us invested in a unicorn company. Best to all Longs.
My optimism. I believe the very segmented and compartmentalized cancer therapy market will be transformed into a single large green field opportunity because DCVax technology platform is a broad-spectrum cancer vaccine. I want to emphasize vaccine (efficacy, non-toxic, and immune memory) as opposed to drug (single antigen target, high risk for toxicity, and not-a-cure).
We Longs all need to stick together, remain disciplined, and trust our due diligence. The market manipulators are still trying to gaslight us into selling, trading, and or lend out our shares. The true potential though is to just hold. Short term has a major asymmetric upside opportunity, and long-term has us invested in a unicorn company. Best to all Longs.
Bullish
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
